About Innovate Biopharmaceuticals

Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Our pipeline includes drug candidates for celiac disease, NASH, Crohn's, and ulcerative colitis. Innovate is led by a strong management team with extensive drug development experience and a history of bringing novel therapeutics to market. All global rights to the products, which are backed by more than 150 patents worldwide, are owned by the company.


Innovate is currently developing three clinical stage assets:

Larazotide Acetate

  • INN-202 currently in Phase 3 for the treatment of celiac disease (CeD) with Fast Track designation
  • INN-217 Preclinical for nonalcoholic steatohepatitis (NASH ) alone and/or in combination with other agent
  • INN-289 Preclinical for a subset of Crohn's disease (CD)

5-ASA + 4-APAA

  • INN-108 Phase 1 for mild to moderate ulcerative colitis (UC), and a gastrointestinal orphan disease in a convenient liquid formulation

Secretin stimulated magnetic resonance cholangiopancreatography

  • INN-329 entering Phase 3 for magnetic resonance cholangiopancreatography (MRCP)
Subscribe to Receive Innovate News and Updates By Email